PD-L1 antibody
-
- Target See all PD-L1 Antibodies
- PD-L1 (CD274 (PD-L1))
-
Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This PD-L1 antibody is un-conjugated
-
Application
- Flow Cytometry (FACS)
- Brand
- Ultra-LEAF™
- Cross-Reactivity
- Chlorocebus aethiops (Green monkey) (Cercopithecus aethiops), Chimpanzee, Marmoset, Squirrel Monkey (Saimiri spec.), Green Monkey (Chlorocebus sabaeus)
- Purification
- The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
- Sterility
- 0.2 μm filtered
- Endotoxin Level
-
Endotoxin level is <0.01 EU/μg of the protein (<0.001 ng/μg of the protein) as determined by the LAL test.
- Clone
- 29E-2A3
- Isotype
- IgG2b kappa
- Top Product
- Discover our top product PD-L1 Primary Antibody
-
-
- Application Notes
- Optimal working dilution should be determined by the investigator.
- Restrictions
- For Research Use only
-
- Concentration
- 1.0 mg/mL
- Preservative
- Azide free
- Handling Advice
- This Ultra-LEAF™ solution contains no preservative, handle under aseptic conditions
- Storage
- 4 °C
- Storage Comment
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
- Target
- PD-L1 (CD274 (PD-L1))
- Alternative Name
- CD274 (PD-L1 Products)
- Background
- CD274, also known as PD-L1 and B7-H1, is type I transmembrane glycoprotein that serves as a ligand for CD279 (PD-1). This interaction is believed to regulate the balance between the stimulatory and inhibitory signals needed for responses to microbes and maintenance of self-tolerance. CD274 is involved in the costimulation of T cell proliferation and IL-10 and IFN-γ production in an IL-2-dependent and CD279-independent manner. Conflicting data has shown that CD274 can inhibit T cell proliferation and cytokine production, and alternatively, enhance T cell activation. Other studies suggest that CD274 may signal bidirectionally, raising interesting implications for its expression in a wide variety of cell types, including T and B cells, antigen-presenting cells, and nonhematopoietic cells.
- Pathways
- Cancer Immune Checkpoints
-